{
    "Rank": 807,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01091636",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "NCCCTS-06-222"
                },
                "Organization": {
                    "OrgFullName": "National Cancer Center, Korea",
                    "OrgClass": "OTHER_GOV"
                },
                "BriefTitle": "Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer",
                "OfficialTitle": "Randomized Trial of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "February 2020",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "March 2010"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "January 10, 2020",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "January 10, 2020",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "March 23, 2010",
                "StudyFirstSubmitQCDate": "March 23, 2010",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "March 24, 2010",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "February 12, 2020",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "February 17, 2020",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Sang-Yoon Park",
                    "ResponsiblePartyInvestigatorTitle": "Gynecologic Oncologist, Center for Gynecologic Cancer",
                    "ResponsiblePartyInvestigatorAffiliation": "National Cancer Center, Korea"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "National Cancer Center, Korea",
                    "LeadSponsorClass": "OTHER_GOV"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Ajou University",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes",
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No",
                "IsUSExport": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "The current standard treatment for ovarian cancer, tubal cancer, and primary peritoneal cancer is maximal cytoreductive surgery followed by chemotherapy. Recent randomized trials of Gynecologic Oncology Group (GOG) revealed the survival gain in intraperitoneal chemotherapy compared to the intravenous chemotherapy after the optimal cytoreduction in ovarian cancer (GOG#104, GOG#114, GOG#172). Experts attributed such survival gain to the earlier cycles of intraperitoneal chemotherapy when adhesion was minimal from extensive cytoreductive procedures.\n\nHyperthermia has an anti-cancer activity itself. Especially, hyperthermia promotes chemotherapy to penetrate deeper into the cancer tissue. Therefore, the combination of intraperitoneal chemotherapy with hyperthermia theoretically could lead to higher response rate and better survival outcomes.\n\n*HIPEC: hyperthermic intraperitoneal chemotherapy\n\nThere will be an interim analysis when 50% of patients are enrolled.\n\nAt the interim analysis, a statistical test will be performed. The nominal significance levels will be determined later. The exact nominal significance level will be determined based on the exact number of events at the time of the interim analysis. The Stopping boundaries will be calculated using an O'Brien-Fleming error spending function",
                "DetailedDescription": "If a patient is allocated to operation to remove ovarian cancer and metastatic disease in the abdomen, this trial could be considered. Before operation, laboratory test results, image result, patient's medical history, and baseline quality of life will be checked and reviewed.\n\nWhen optimal cytoreduction (residual tumor<1cm) is attained, this HIPEC (hyperthermic intraperitoneal chemotherapy) could be considered. For the primary advanced epithelial ovarian cancer, HIPEC will be performed at random. For the recurrent ovarian cancer, HIPEC will be performed after completion of cytoreductive procedures. Usually, HIPEC takes one and half hours after cytoreductive surgery.\n\nAfter cytoreductive surgery followed by HIPEC, adjuvant chemotherapy will be added. The cycle of chemotherapy will be determined according to the patients' clinical outcomes. The laboratory test results, image result, patient's medical history, and baseline quality of life will be checked after the operation, during chemotherapy, and after chemotherapy.\n\nCytoreduction: an operation to remove ovarian cancer and its metastatic disease\n\nThere will be an interim analysis when 50% of patients are enrolled.\n\nAt the interim analysis, a statistical test will be performed. The nominal significance levels will be determined later. The exact nominal significance level will be determined based on the exact number of events at the time of the interim analysis. The Stopping boundaries will be calculated using an O'Brien-Fleming error spending function"
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Epithelial Ovarian Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2",
                        "Phase 3"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Parallel Assignment",
                    "DesignInterventionModelDescription": "HIPEC vs. no HIPEC after primary cytoreductive surgery or interval cytoreductive surgery",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "Single",
                        "DesignMaskingDescription": "Blinded to the participants",
                        "DesignWhoMaskedList": {
                            "DesignWhoMasked": [
                                "Participant"
                            ]
                        }
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "184",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "HIPEC",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Ovarian Cancer after primary cytoreductive surgery or interval cytoreductive surgery",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Procedure: Hyperthermic Intraperitoneal Chemotherapy"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "No HIPEC",
                            "ArmGroupType": "No Intervention",
                            "ArmGroupDescription": "Primary cytoreductive surgery or interval cytoreductive surgery"
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "Hyperthermic Intraperitoneal Chemotherapy",
                            "InterventionDescription": "41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "HIPEC"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Belmont Instrument Corporation"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Progression free survival",
                            "PrimaryOutcomeDescription": "To assess progression free survival rate during 2 years after Intraoperative Hyperthermic Intraperitoneal Chemotherapy followed by Intravenous Chemotherapy in Patients with Ovarian Cancer.",
                            "PrimaryOutcomeTimeFrame": "2 years"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Overall survival, quality of life",
                            "SecondaryOutcomeDescription": "Ovarian cancer patients after HIPEC are observed complication and 3-year survival rate.\n\nOvarian cancer patients after HIPEC are analyzed quality of life.",
                            "SecondaryOutcomeTimeFrame": "3 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nDisease status Primary ovarian cancer, tubal cancer, and primary peritoneal cancer (Stage III or more)\nResidual tumor < 1cm after completion of cytoreductive surgery\nAge < 75 year\nExpected survival > 3 months\nPerformance status: ECOG 0-1\nAdequate bone marrow function Hb \u22658 g/dl (After correction in case of iron deficient anemia) WBC \u2265 3,000/mm3, Platelet \u2265 100,000/mm3\nAdequate renal function Creatinine \u2264 1.5 mg/dl\nAdequate hepatic function Bilirubin \u2264 1.5 mg/dl and AST and ALT \u2264 80 IU/L\nOptimal cardiopulmonary function for surgery\nVoluntary participation after getting written informed consent.\n\nExclusion Criteria:\n\nUnresectable extraperitoneal metastasis (brain, bone, lung parenchyme, and supraclavicular lymph node)\nSuboptimal debulking (residual tumor > 1cm)\nPrevious History of other malignancies (except excision of skin cancer, thyroid cancer)\nSerious heart disease or renal failure\nSerious cardiopulmonary insufficiency\nUncontrolled infection\nUncontrolled intercurrent disease\nPsychogenic disorder\nPatients who are suitable candidates by legally\nPregnant or breast-feeding patients\nPatients who are unsuitable candidates by doctor's decision\nMMMT\nCancer tissue is not confirmed during surgery after neo-adjuvant chemotherapy",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MaximumAge": "75 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Child",
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Sang-Yoon Park, MD, Ph.D.",
                            "OverallOfficialAffiliation": "National Cancer Center in Korea",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "National Cancer Center",
                            "LocationCity": "Goyang",
                            "LocationState": "Gyeonggi",
                            "LocationZip": "410-769",
                            "LocationCountry": "Korea, Republic of"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "ReferenceList": {
                    "Reference": [
                        {
                            "ReferencePMID": "19169758",
                            "ReferenceType": "result",
                            "ReferenceCitation": "Lim MC, Kang S, Choi J, Song YJ, Park S, Seo SS, Park SY. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol. 2009 Apr;16(4):993-1000. doi: 10.1245/s10434-008-0299-y. Epub 2009 Jan 24."
                        },
                        {
                            "ReferencePMID": "35712968",
                            "ReferenceType": "derived",
                            "ReferenceCitation": "Kim JH, Lee DE, Lee Y, Ha HI, Chang YJ, Chang SJ, Park SY, Lim MC. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01). J Gynecol Oncol. 2022 Jul;33(4):e54. doi: 10.3802/jgo.2022.33.e54. Epub 2022 May 31."
                        },
                        {
                            "ReferencePMID": "35262624",
                            "ReferenceType": "derived",
                            "ReferenceCitation": "Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY; HIPEC for Ovarian Cancer Collaborators. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surg. 2022 May 1;157(5):374-383. doi: 10.1001/jamasurg.2022.0143."
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "Undecided"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000010051",
                            "ConditionMeshTerm": "Ovarian Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000077216",
                            "ConditionMeshTerm": "Carcinoma, Ovarian Epithelial"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000004701",
                            "ConditionAncestorTerm": "Endocrine Gland Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000010049",
                            "ConditionAncestorTerm": "Ovarian Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000000291",
                            "ConditionAncestorTerm": "Adnexal Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005831",
                            "ConditionAncestorTerm": "Genital Diseases, Female"
                        },
                        {
                            "ConditionAncestorId": "D000052776",
                            "ConditionAncestorTerm": "Female Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005261",
                            "ConditionAncestorTerm": "Female Urogenital Diseases and Pregnancy Complications"
                        },
                        {
                            "ConditionAncestorId": "D000091642",
                            "ConditionAncestorTerm": "Urogenital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005833",
                            "ConditionAncestorTerm": "Genital Neoplasms, Female"
                        },
                        {
                            "ConditionAncestorId": "D000014565",
                            "ConditionAncestorTerm": "Urogenital Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000091662",
                            "ConditionAncestorTerm": "Genital Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000004700",
                            "ConditionAncestorTerm": "Endocrine System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000006058",
                            "ConditionAncestorTerm": "Gonadal Disorders"
                        },
                        {
                            "ConditionAncestorId": "D000002277",
                            "ConditionAncestorTerm": "Carcinoma"
                        },
                        {
                            "ConditionAncestorId": "D000009375",
                            "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
                        },
                        {
                            "ConditionAncestorId": "D000009370",
                            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M12664",
                            "ConditionBrowseLeafName": "Ovarian Neoplasms",
                            "ConditionBrowseLeafAsFound": "Ovarian Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M1704",
                            "ConditionBrowseLeafName": "Carcinoma, Ovarian Epithelial",
                            "ConditionBrowseLeafAsFound": "Ovarian Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M2455",
                            "ConditionBrowseLeafName": "Hyperthermia",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8154",
                            "ConditionBrowseLeafName": "Fever",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7553",
                            "ConditionBrowseLeafName": "Endocrine Gland Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12662",
                            "ConditionBrowseLeafName": "Ovarian Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M3333",
                            "ConditionBrowseLeafName": "Adnexal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8633",
                            "ConditionBrowseLeafName": "Genital Diseases, Female",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2877",
                            "ConditionBrowseLeafName": "Genital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M2876",
                            "ConditionBrowseLeafName": "Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M26783",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M13817",
                            "ConditionBrowseLeafName": "Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8089",
                            "ConditionBrowseLeafName": "Female Urogenital Diseases and Pregnancy Complications",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8635",
                            "ConditionBrowseLeafName": "Genital Neoplasms, Female",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M17005",
                            "ConditionBrowseLeafName": "Urogenital Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7552",
                            "ConditionBrowseLeafName": "Endocrine System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8853",
                            "ConditionBrowseLeafName": "Gonadal Disorders",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12010",
                            "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12005",
                            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T4352",
                            "ConditionBrowseLeafName": "Ovarian Cancer",
                            "ConditionBrowseLeafAsFound": "Ovarian Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "T4354",
                            "ConditionBrowseLeafName": "Ovarian Epithelial Cancer",
                            "ConditionBrowseLeafAsFound": "Ovarian Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BXS",
                            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC19",
                            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC26",
                            "ConditionBrowseBranchName": "Wounds and Injuries"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M5872",
                            "InterventionBrowseLeafName": "Cisplatin",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}